FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W561082783> ?p ?o ?g. }

• W561082783 abstract "How to evaluate a new antiarrhythmic drug: The challenge of sudden cardiac death.- How to evaluate a new antiarrhythmic drug: The challenge of sudden cardiac death.- Pre-Clinical Evaluation of a New Antiarrhythmic Agent.- Relationships between effects on cardiac electrophysiology and antiarrhythmic efficacy.- What animal models should be used to define antiarrhythmic efficacy: acute dog models?.- Description of chronic canine myocardial infaction models suitable for the electropharmacologic evaluation of new antiarrhythmic drugs.- Non-canine animal models for evaluating antiarrhythmic efficacy General Group Discussion: Animal Models.- Defining the pharmacodynamics and pharmacokinetics of new antiarrhythmic drugs General Group Discussion: Pharmacology.- Chronic Studies in Patients with Non-Hemodynamically Significant Ventricular Arrhythmics.- How should Holter monitoring analysis be performed?.- Long-term ambulatory electrocardiographic recording in the determination of efficacy of new antiarrhythmic agents.- Evaluation of antiarrhythmic drugs. Should the Lown classification be used as a measure of efficacy?.- General Group Discussion: Holter Monitoring.- Study Designs: Chronic Patients.- New means of evaluating antiarrhythmic drugs.- Parallel or crossover designs in evaluation of antiarrhythmic therapy.- General Group Discussion: Study Designs: Chronic Patients.- Remarks: J. Richard Crout, Director, Bureau of Drugs Food and Drug Administration.- Acute Studies in Patients with Hemodynamically Significant Significant Ventricular Arrhythmias.- Acute drug testing as a part of a systematic approach to antiarrhythmic drug therapy.- What is the role of electrophysiology in drug testing? General Group Discussion: Electrophysiology.- What should the study design be to test new antiarrhythmic drugs in patients with acute myocardial infarction, digitalis toxicity and other acute problems General Group Discussion: Study Designs in Acute Patients.- Special Considerations.- What baseline electrophysiologic data should be obtained (plus discussion).- Assessment of the hemodynamic and inotropic effects of antiarrhythmic drugs (plus discussion).- Evaluation of drug treatment in supraventricular arrhythmias (plus discussion).- How should long-term safety of a new antiarrhythmic drug be defined (plus discussion).- How should one manage emergency drug requests and their data (puls discussion).- How does one evaluate and use outside U.S.A. data in the new drug application (plus discussion)." @default.
• W561082783 created "2016-06-24" @default.
• W561082783 creator A5086647305 @default.
• W561082783 date "1981-01-01" @default.
• W561082783 modified "2023-09-23" @default.
• W561082783 title "The Evaluation of new antiarrhythmic drugs : proceedings of the Symposium on How to Evaluate a New Antiarrhythmic Drug: the Evaluation of New Antiarrhythmic Agents for the Treatment of Ventricular Arrhythmias, held at Philadelphia, Pennsylvania, October 8-9, 1980" @default.
• W561082783 hasPublicationYear "1981" @default.
• W561082783 type Work @default.
• W561082783 sameAs 561082783 @default.
• W561082783 citedByCount "1" @default.
• W561082783 crossrefType "book" @default.
• W561082783 hasAuthorship W561082783A5086647305 @default.
• W561082783 hasConcept C126322002 @default.
• W561082783 hasConcept C164705383 @default.
• W561082783 hasConcept C177713679 @default.
• W561082783 hasConcept C2775935837 @default.
• W561082783 hasConcept C2778131192 @default.
• W561082783 hasConcept C2780035454 @default.
• W561082783 hasConcept C2780074459 @default.
• W561082783 hasConcept C500558357 @default.
• W561082783 hasConcept C71924100 @default.
• W561082783 hasConcept C98274493 @default.
• W561082783 hasConceptScore W561082783C126322002 @default.
• W561082783 hasConceptScore W561082783C164705383 @default.
• W561082783 hasConceptScore W561082783C177713679 @default.
• W561082783 hasConceptScore W561082783C2775935837 @default.
• W561082783 hasConceptScore W561082783C2778131192 @default.
• W561082783 hasConceptScore W561082783C2780035454 @default.
• W561082783 hasConceptScore W561082783C2780074459 @default.
• W561082783 hasConceptScore W561082783C500558357 @default.
• W561082783 hasConceptScore W561082783C71924100 @default.
• W561082783 hasConceptScore W561082783C98274493 @default.
• W561082783 hasLocation W5610827831 @default.
• W561082783 hasOpenAccess W561082783 @default.
• W561082783 hasPrimaryLocation W5610827831 @default.
• W561082783 hasRelatedWork W13898943 @default.
• W561082783 hasRelatedWork W153148656 @default.
• W561082783 hasRelatedWork W1975192657 @default.
• W561082783 hasRelatedWork W1987191385 @default.
• W561082783 hasRelatedWork W2035563629 @default.
• W561082783 hasRelatedWork W2057324409 @default.
• W561082783 hasRelatedWork W2151295088 @default.
• W561082783 hasRelatedWork W2353690132 @default.
• W561082783 hasRelatedWork W2396202904 @default.
• W561082783 hasRelatedWork W2403159542 @default.
• W561082783 hasRelatedWork W2409976895 @default.
• W561082783 hasRelatedWork W2416894951 @default.
• W561082783 hasRelatedWork W2461767595 @default.
• W561082783 hasRelatedWork W2464583409 @default.
• W561082783 hasRelatedWork W2477759098 @default.
• W561082783 hasRelatedWork W2478197280 @default.
• W561082783 hasRelatedWork W2481752081 @default.
• W561082783 hasRelatedWork W2501446778 @default.
• W561082783 hasRelatedWork W3023506699 @default.
• W561082783 hasRelatedWork W3024418960 @default.
• W561082783 isParatext "false" @default.
• W561082783 isRetracted "false" @default.
• W561082783 magId "561082783" @default.
• W561082783 workType "book" @default.